Posted on May 29th, 2012 by
The newly low cost of Plavix, one of the biggest-selling drugs, is intensifying debate among cardiologists over how to make sure patients get optimal benefit from any blood-thinning medication. A generic version of Plavix became available this month so there is an incentive to switch patients to it…"Professional [medical] societies don't think the overall level of evidence is strong enough to make a wholesale switch" from Plavix to Effient or Brilinta, says Chet Rihal, a cardiologist at the Mayo Clinic, in Rochester, Minn.
Wall Street Journal by Ron Winslow
You must be logged-in to the site to post a comment.